320 related articles for article (PubMed ID: 21305617)
1. Genetic modeling of gliomas in mice: new tools to tackle old problems.
Hambardzumyan D; Parada LF; Holland EC; Charest A
Glia; 2011 Aug; 59(8):1155-68. PubMed ID: 21305617
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.
Brennan C; Momota H; Hambardzumyan D; Ozawa T; Tandon A; Pedraza A; Holland E
PLoS One; 2009 Nov; 4(11):e7752. PubMed ID: 19915670
[TBL] [Abstract][Full Text] [Related]
3. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous development of intratumoral heterogeneity in a transposon-induced mouse model of glioma.
Sumiyoshi K; Koso H; Watanabe S
Cancer Sci; 2018 May; 109(5):1513-1523. PubMed ID: 29575648
[TBL] [Abstract][Full Text] [Related]
5. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.
Sun Y; Zhang W; Chen D; Lv Y; Zheng J; Lilljebjörn H; Ran L; Bao Z; Soneson C; Sjögren HO; Salford LG; Ji J; French PJ; Fioretos T; Jiang T; Fan X
Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3538-43. PubMed ID: 24550449
[TBL] [Abstract][Full Text] [Related]
6. Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Herting CJ; Chen Z; Pitter KL; Szulzewsky F; Kaffes I; Kaluzova M; Park JC; Cimino PJ; Brennan C; Wang B; Hambardzumyan D
Glia; 2017 Dec; 65(12):1914-1926. PubMed ID: 28836293
[TBL] [Abstract][Full Text] [Related]
7. PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas.
Noorani I; de la Rosa J; Choi YH; Strong A; Ponstingl H; Vijayabaskar MS; Lee J; Lee E; Richard-Londt A; Friedrich M; Furlanetto F; Fuente R; Banerjee R; Yang F; Law F; Watts C; Rad R; Vassiliou G; Kim JK; Santarius T; Brandner S; Bradley A
Genome Biol; 2020 Jul; 21(1):181. PubMed ID: 32727536
[TBL] [Abstract][Full Text] [Related]
8. Mouse models of brain tumors and their applications in preclinical trials.
Fomchenko EI; Holland EC
Clin Cancer Res; 2006 Sep; 12(18):5288-97. PubMed ID: 17000661
[TBL] [Abstract][Full Text] [Related]
9. Genetic modeling of glioma formation in mice.
Begemann M; Fuller GN; Holland EC
Brain Pathol; 2002 Jan; 12(1):117-32. PubMed ID: 11770894
[TBL] [Abstract][Full Text] [Related]
10. Genetically engineered mouse models of diffuse gliomas.
Schmid RS; Vitucci M; Miller CR
Brain Res Bull; 2012 May; 88(1):72-9. PubMed ID: 21684324
[TBL] [Abstract][Full Text] [Related]
11. Glioma: an overview of current classifications, characteristics, molecular biology and target therapies.
Zeng T; Cui D; Gao L
Front Biosci (Landmark Ed); 2015 Jun; 20(7):1104-15. PubMed ID: 25961548
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer.
Connolly NP; Stokum JA; Schneider CS; Ozawa T; Xu S; Galisteo R; Castellani RJ; Kim AJ; Simard JM; Winkles JA; Holland EC; Woodworth GF
PLoS One; 2017; 12(3):e0174557. PubMed ID: 28358926
[TBL] [Abstract][Full Text] [Related]
13. Modeling and preclinical trials for gliomas.
Salpietro M; Holland EC
Clin Neurosurg; 2005; 52():104-11. PubMed ID: 16626060
[No Abstract] [Full Text] [Related]
14. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic implications of NF1 gene alterations in diffuse gliomas.
Vizcaíno MA; Shah S; Eberhart CG; Rodriguez FJ
Hum Pathol; 2015 Sep; 46(9):1323-30. PubMed ID: 26190195
[TBL] [Abstract][Full Text] [Related]
16. Using mice to decipher the molecular genetics of brain tumors.
Hesselager G; Holland EC
Neurosurgery; 2003 Sep; 53(3):685-94; discussion 695. PubMed ID: 12943584
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of new transgenic mouse models in glioma research.
Sonabend AM; Ulasov IV; Lesniak MS
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S7-13. PubMed ID: 18076321
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
19. Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.
Gutmann DH
J Child Neurol; 2008 Oct; 23(10):1186-94. PubMed ID: 18952585
[TBL] [Abstract][Full Text] [Related]
20. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.
Oh H; Hwang I; Jang JY; Wu L; Cao D; Yao J; Ying H; Li JY; Yao Y; Hu B; Wang Q; Zheng H; Paik J
Cancer Res; 2021 Mar; 81(6):1528-1539. PubMed ID: 33509942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
